Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.
Outlook Therapeutics will show its money results soon, and experts think the company might lose a small amount of money per share. When a company loses money, watch if they're getting closer to making a profit or if the losses are getting bigger.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.